Visual outcomes of small-aperture IOL implant in post-laser refractive eyes

December 17, 2020

By David Hutton
Alex Delaney-Gesing

Video

Robert Ang, MD, discusses highlights of his AAO 2020 presentation on a study analyzing the vIsual outcomes of a small-aperture IOL implantation in patients with a history of post-laser refractive surgery.

Robert Ang, MD, director, Refractive Surgery Department, Asian Eye Institute (Philippines), discusses highlights of his AAO 2020 presentation on a study titled, "Visual outcomes of small-aperture IOL implantation in post-laser refractive eyes."

See more AAO coverage

Recent Videos

1 KOL is featured in this series.

1 KOL is featured in this series.

1 KOL is featured in this series.

1 KOL is featured in this series.

This series features 1 KOL.

This series features 1 KOL.

This series features 1 KOL.

Video 2 - 1 KOL is featured in, "Advances in Technology for SMILE procedure"

Video 1 - 1 KOL is featured in, "Overview of Small Incision Lenticule Extraction (SMILE)"

Vicki Chan, MD, shares pearls for leveraging the power of social media in health care

Related Content

Nicox announces recruitment of last patient in US in Denali Phase 3 trial of NCX 470

Nicox announces recruitment of last patient in US in Denali Phase 3 trial of NCX 470

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

CHAMP Phase 3 trial: Efficacy of NVK002 for controlling pediatric myopia over 3 years

CHAMP Phase 3 trial: Efficacy of NVK002 for controlling pediatric myopia over 3 years

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention

FDA approves faricimab-svoa 6.0 mg single-dose prefilled syringe for use in the treatment of wet AMD, DME and RVO

FDA approves faricimab-svoa 6.0 mg single-dose prefilled syringe for use in the treatment of wet AMD, DME and RVO

Test evaluates, quantifies ocular dominance for robust monovision correction

Test evaluates, quantifies ocular dominance for robust monovision correction

Related Content

Nicox announces recruitment of last patient in US in Denali Phase 3 trial of NCX 470

Nicox announces recruitment of last patient in US in Denali Phase 3 trial of NCX 470

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

CHAMP Phase 3 trial: Efficacy of NVK002 for controlling pediatric myopia over 3 years

CHAMP Phase 3 trial: Efficacy of NVK002 for controlling pediatric myopia over 3 years

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention

FDA approves faricimab-svoa 6.0 mg single-dose prefilled syringe for use in the treatment of wet AMD, DME and RVO

FDA approves faricimab-svoa 6.0 mg single-dose prefilled syringe for use in the treatment of wet AMD, DME and RVO

Test evaluates, quantifies ocular dominance for robust monovision correction

Test evaluates, quantifies ocular dominance for robust monovision correction

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.